COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Goserelin (Primary) ; Letrozole (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms CompLEEment-1
- Sponsors Novartis Pharmaceuticals
- 21 Mar 2017 Planned End Date changed from 9 Nov 2020 to 14 May 2021.
- 21 Mar 2017 Planned primary completion date changed from 9 Nov 2020 to 30 Nov 2019.
- 31 Dec 2016 Status changed from not yet recruiting to recruiting.